Fig. 1: Co-relationship between clinical factors and the expression of TRIM36 in prostate cancer. | Cell Death & Disease

Fig. 1: Co-relationship between clinical factors and the expression of TRIM36 in prostate cancer.

From: TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways

Fig. 1

a TRIM36 was upregulated in our mRNA microarray data. b Relative mRNA expression of TRM36 in PCa tissues with different Gleason scores compared with the corresponding non-tumor tissues. The TRIM36 mRNA level is higher in the PCa tissues with low Gleason scores. c Different immunohistochemistry results for TRIM36 expression in a tissue microarray. Left: Negative TRIM36 expression. Right: Strong TRIM36 expression. d Kaplan–Meier biochemical recurrence-free survival curves for PCa patients based on TRIM36 expression levels. Patients with positive TRIM36 expression had obviously longer survival times than those with negative TRIM36 expression (log-rank test, P < 0.001)

Back to article page